Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arch Biopartners gets US patent for brain tumor targeting peptides
Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty. This U.S. patent
Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty. This U.S. patent
These targeted therapies are being developed at a time when cardiovascular, neurodegenerative and metabolic lifestyle diseases are approaching epidemic stages, and viral and bacterial infectious disease conditions are
DMD is a recessive X-linked form of muscular dystrophy, which results in muscle degeneration, difficulty walking, breathing and ultimately death. Diagnosis typically occurs between the ages of 2
This agreement will complement Flexion’s existing manufacturing relationship with Evonik Corporation and create redundant supply for FX006, which is an intra-articular (IA) sustained-release steroid for the treatment of
Minerva Biotechnologies discovered a naturally occurring, primitive growth factor that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state. Scientists believe that because these
Insulin glargine 300 units/ml is indicated for the treatment of diabetes mellitus in adults and is a novel formulation of the glargine molecule Lantus (insulin glargine 100 units/mL)
Today the PBM, CVS Caremark published their 2016 Standard Formulary List of Excluded Drugs for their commercial clients. Effective from January 1, 2016 Zubsolv has been removed from
This latest update to the IBgard market authorization allows for the following additional claims on the product label: – helps improve/relieve symptoms of IBS within 24 hours,– helps
This approval allows for the marketing of Omidria in all EU member states plus Iceland, Lichtenstein, and Norway. Cataract surgery and lens replacement are among the most common
The divestiture includes all of IBAM NA’s cyclotron sites and its research and development facilities. Terms of the transaction were not disclosed. IBA Molecular is jointly owned by